EQT

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapeutic products for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts are dedicated to addressing disabling symptoms associated with conditions affecting the nervous system, such as Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma aims to enhance the quality of life and improve patient outcomes for those suffering from these challenging disorders.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

SHL Medical AG specializes in the design, development, and manufacturing of advanced drug delivery systems, including auto-injectors, pen injectors, and inhaler systems. Founded in 1989 and headquartered in Zug, Switzerland, the company serves pharmaceutical and biotech firms around the globe. In addition to its core product offerings, SHL Medical provides comprehensive services such as final assembly, labeling, and packaging. The company is committed to maintaining high-quality standards and adhering to strict regulatory requirements, ensuring that it delivers innovative and reliable solutions tailored to meet the needs of its clients.

FoRx Therapeutics AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company is dedicated to developing innovative therapeutics for cancer treatment, specifically targeting key molecular pathways associated with DNA replication stress. By focusing on these novel pathways, FoRx aims to create first-in-class compounds that provide a new approach to targeted anticancer therapies. Through its research and development efforts, FoRx Therapeutics seeks to advance the healthcare industry's capabilities in combating cancer effectively.

SHL Medical AG specializes in the design, development, and manufacturing of advanced drug delivery systems, including auto-injectors, pen injectors, and inhaler systems. Founded in 1989 and headquartered in Zug, Switzerland, the company serves pharmaceutical and biotech firms around the globe. In addition to its core product offerings, SHL Medical provides comprehensive services such as final assembly, labeling, and packaging. The company is committed to maintaining high-quality standards and adhering to strict regulatory requirements, ensuring that it delivers innovative and reliable solutions tailored to meet the needs of its clients.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Open Systems AG, established in 1990 and headquartered in Zurich, Switzerland, specializes in providing comprehensive managed security services to global enterprises, NGOs, and institutions. The company offers a range of services, including network security, application delivery, identity management, and global connectivity, ensuring secure and reliable IT networks and business-critical applications. Open Systems' offerings encompass distributed and enterprise firewall services, WAN encryption, network security monitoring, and incident response, among others. Serving diverse sectors such as finance, healthcare, and government, the company aims to deliver effective security solutions tailored to clients' unique needs.

CHEP is a leading global provider of supply chain solutions, specializing in enhancing efficiency and sustainability for its customers. The company offers a range of services, including asset management and repair for unit load devices (ULDs), galley carts, and ground support equipment through its CHEP Aerospace Solutions division, headquartered in Zurich, Switzerland. This division manages the world's largest independent fleet of ULDs and operates a comprehensive global network for the maintenance and repair of containers, pallets, and inflight food service equipment. By providing tailor-made outsourcing solutions, CHEP enables airlines to focus on their core operations of transporting passengers and cargo while achieving significant cost savings and operational benefits. The company serves over 80 airlines worldwide, leveraging its unique capabilities and insights to help clients improve their logistics and supply chain management.

Kuoni Destination Management is a Switzerland-based company that specializes in providing comprehensive destination management services for the travel and hospitality industries. The company focuses on event solutions, offering a range of services that include event development, budgeting, creative direction, and logistical support for virtual, hybrid, and live events. Its expertise encompasses entertainment, audiovisual technology, transportation, and coordination of activities such as gala dinners and public events. Kuoni Destination Management aims to deliver innovative and memorable experiences while ensuring seamless execution and attention to detail in all aspects of event planning and management.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

Kuros Biosciences AG is a biopharmaceutical company based in Schlieren, Switzerland, dedicated to the discovery, development, and commercialization of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has developed a robust pipeline of biopharmaceuticals targeting chronic diseases. Its key products include Neuroseal, a novel biomaterial for dural sealing, and the MagnetOs family of bone graft substitutes used in orthopedic, spinal, and dental applications. MagnetOs is approved for use in the EU and the US, with further formulations under development for regulatory submission. Kuros also has a range of clinical-stage products, including KUR-111 and KUR-113, which have completed Phase II clinical trials for treating specific bone fractures. The company has engaged in significant clinical research, enrolling over 600 patients in multinational trials, generating promising data regarding safety and efficacy in various applications, particularly within orthobiologics.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Evidensia Djursjukvård AB is a veterinary clinic chain headquartered in Stockholm, Sweden, operating over 180 clinics and hospitals across Sweden, Norway, Denmark, Finland, Germany, Holland, and Switzerland. The company provides a comprehensive range of animal care services, including veterinary care, food, medicine, and supplies for various pets, such as dogs, cats, small animals, exotic animals, and horses. Through its extensive network, Evidensia aims to deliver quality veterinary services to pet owners in multiple countries.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

Swiss Smile is a dental service provider based in Switzerland, established in 2003 by Haleh Bronner and Golnar Signer. The company specializes in a comprehensive range of dental treatments that include prevention, preservation, tooth extraction and replacement, teeth straightening, beautification, medical procedures, and hygiene treatments. In addition to these services, Swiss Smile also conducts dentistry classes in schools, promoting dental health education. With operations in several cities including Zurich, Baden, Bulach, St. Moritz, Suhr, and Winterthur, Swiss Smile aims to deliver high-quality dental care to a diverse clientele across the region.

PharmaZell GmbH is a German company that specializes in the development and production of generic active pharmaceutical ingredients (APIs), controlled substances, and amino acids. Founded in 1947 and headquartered in Raubling, Germany, it operates production facilities in Switzerland, Italy, and India, along with a sales branch in the United States. The company provides services for formulation development and regulatory documentation, catering to both originator and generic pharmaceutical sectors. With a focus on delivering tailored solutions through a flexible technology platform, PharmaZell aims to address the specific needs of its clients across the global pharmaceutical industry. The company is committed to ethical practices and prioritizes environmental responsibility, ensuring that it maintains strong relationships with its business partners and employees.

Okairos AG is a biopharmaceutical company headquartered in Basel, Switzerland, with operations in Rome and Naples, Italy. The company specializes in the discovery and development of genetic T-cell vaccines, focusing on conditions such as hepatitis C virus. Okairos also excels in gene delivery technologies, providing expertise in scalable viral-vector manufacturing processes. This enables other biotech firms to transition genetic vaccines and medicinal products from preclinical stages to commercial readiness, utilizing advanced good manufacturing practice (GMP) facilities. Previously a subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa, Okairos is dedicated to advancing innovative therapeutic solutions in the healthcare sector.

4-Antibody AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of human antibody therapeutics with a focus on immuno-oncology. Founded in 2002, the company utilizes its proprietary Retrocyte Display technology, which generates therapeutic antibody drug candidates from human antibody libraries expressed in mammalian B-lineage lymphocytes. In addition to providing its drug discovery platform to pharmaceutical partners, 4-Antibody is actively developing a pipeline of preclinical antibody programs targeting various immune checkpoints, including GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3.

DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH).

4-Antibody AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of human antibody therapeutics with a focus on immuno-oncology. Founded in 2002, the company utilizes its proprietary Retrocyte Display technology, which generates therapeutic antibody drug candidates from human antibody libraries expressed in mammalian B-lineage lymphocytes. In addition to providing its drug discovery platform to pharmaceutical partners, 4-Antibody is actively developing a pipeline of preclinical antibody programs targeting various immune checkpoints, including GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3.